Clinical trials refer to the series of scientific studies carried out in humans that validate the research and development stages in the medicine discovery process. They are a crucial step, and subject to rigorous regulatory controls, in obtaining a marketing authorization and determining the optimal use of a medicinal product to ensure therapeutic benefit for patients.
HIGH SCIENTIFIC STANDARDS
The Group’s clinical trials are managed by expert teams with high, exacting standards. Proper trial conduct requires good organization, involving teams responsible for international coordination and local teams present in 18 countries, to make it possible to manage clinical trials worldwide.
The global presence of Servier R&D therefore plays a fundamental role in the scientific influence of the company, allowing the development of innovative medicines corresponding to different needs of patients.
Servier is committed to involving patients, directly or through patient associations, to develop medicines that best meet their needs. Patient representatives are already involved in 25% of Group clinical trial protocols in order to make sure all aspects of a disease and any inherent constraints are accounted for.
Digital technology and data processing increase agility, efficiency, and productivity to speed up the research process, the iterative molecule identification procedure, and clinical trials, while also developing a more detailed understanding of patients.
SCORE, the Servier program that digitizes clinical trials, falls within this ambition as it encourages remote dialogue between patients and medical and scientific teams by providing access to data in real time, therefore making it easier to make decisions.
The FederateS platform, meanwhile, is an intuitive and collaborative workspace for sharing and enhancing data within teams, to accelerate the various research stages.
Servier publishes 100% of the results of its European clinical trials on the European Union Clinical Trials Register website.
Servier complies with the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) 5 clinical-trial transparency principles in its clinical trials.
Servier recognizes the importance of Investigator-Initiated Trials (IITs) conducted by third-party sponsors. For this purpose, Servier is committed to support medical and scientific research which contributes to better understand the Group’s therapeutic solutions as well as to explore new opportunities to address unmet patient medical needs.